All In Biotech

NDA 018802 · Hospira

Bacteriostatic Water For Injection In Plastic Container

Sterile Water For Injection · N/A

Last checked: Nov 19, 2026Latest source record: Dec 22, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1982

Oct 27, 1982

Approved uses

1

Original approval plus efficacy supplements

Registered trials

555

138 Phase 3, 52 recruiting

FAERS reports

415

172 serious, 12 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

Boxed Warning Multiple-dose Vial WARNING: NOT FOR USE IN NEONATES.

What it is approved for

From the label in effect Oct 26, 2026.

INDICATIONS AND USAGE This parenteral preparation is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered.

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 27, 1982 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER · STERILE WATER FOR INJECTION 100% · LIQUID, N/A · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Sterile Water For Injection" as an intervention, any sponsor and status, largest first.

All 555 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product dose omission issue78
  • weight increased43
  • weight decreased39
  • headache33
  • therapy interrupted33
  • off label use28
  • pain28
  • drug ineffective24
  • decreased appetite20
  • fatigue17
  • hospitalisation17
  • blood glucose increased16

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20132
20151
20162
20172
20182
20199
202055
202143
202257
202358
202471
202549
202664

Recalls

1 FDA enforcement reports for this application.

  • Sep 6, 2019 · Class II · Terminated

    Lack of Assurance of Sterility

Shortages

FDA's drug shortage list.

  • Current · updated Nov 9, 2026

    Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 13 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.